Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · March 18, 2024

Mutational Analysis of ctDNA in Patients With ER+/HER2− Advanced Breast Cancer Receiving Palbociclib

JCO Precision Oncology


Additional Info

JCO Precision Oncology
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial
JCO Precis Oncol 2024 Feb 01;8(xx)e2300285, I Migliaccio, D Romagnoli, F Galardi, F De Luca, C Biagioni, G Curigliano, C Criscitiello, AM Minisini, E Moretti, E Risi, C Guarducci, A Nardone, L Biganzoli, M Benelli, L Malorni

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading